Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Date:5/12/2008

weeks for a total of 6 doses. All patients will have active RA while on methotrexate. The trial is expected to enroll 70 patients at multiple sites in Europe. The primary endpoint of the study is the ACR20 response, a composite endpoint that indicates a 20% improvement in RA signs and symptoms, at 12 weeks.

Medarex also announced that results from the MDX-1100 Phase 1 trials will be presented at the Digestive Disease Week (DDW) meeting, being held May 17 - 22, 2008 in San Diego. The following abstracts are expected to be the subject of presentations at the DDW 2008 conference:

-- "A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and

Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal

Antibody, in Healthy Subjects" (Abstract #T1145) - Poster presentation

on May 20, 2008 from 12:00 to 2:00 PM CDT.

-- "A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of MDX-1100,

a High-Affinity, Neutralizing, Fully Human IgG1k Anti-CXCL10 (IP10)

Monoclonal Antibody, in Ulcerative Colitis" (Abstract #704) - Oral

presentation on May 20, 2008 from 3:00 to 3:15 PM CDT.

-- "CXCL10 Expression and Biological Activities in Inflammatory Bowel

Disease" (Abstract #W1170) - Poster presentation on May 21, 2008 from

12:00 to 2:00 PM CDT.

These presentations support the development of MDX-1100 for the treatment of inflammatory diseases such as ulcerative colitis and rheumatoid arthritis.

About MDX-1100

MDX-1100 is a fully human antibody that targets CXCL10 (also known as IP-10), a chemokine expressed in association with multiple inflammatory disease indications such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

About Ulcerative Colitis

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colon and is characterized by inflammation and ulceration of the lining of the colon. Sy
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015  Ortho-Clinical Diagnostics, Inc. ... assays under development. The assays address a range of ... injury and cardiac troponin I. The scientific posters will ... Chemistry Annual Meeting to be held July 26 - ... "Ortho Clinical Diagnostics is emerging stronger than ...
(Date:7/29/2015)... July 29, 2015  The Perinatal Quality Foundation ... understanding of the advantages, limitations and clinically appropriate ... other diagnostic tests for pregnant women and their ... the world,s leading provider of diagnostic information services, ... initiative, through a grant. Through ...
(Date:7/29/2015)... 29, 2015  ViaCyte, Inc., a privately-held regenerative medicine company with ... diabetes in clinical trials, today announced the opening of a second ... S afety, T olerability, and E fficacy of VC-01™ ... new site, which is the first in Canada ... Edmonton , Alberta.  The lead ...
Breaking Medicine Technology:Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 2Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 3Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 4ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
... , INDIANAPOLIS, Nov. 16 AMD LASERS, the world ... announced the addition of Bart Waclawik as Chief Operating ... be responsible for daily global operations, procurement, production, quality ... he will lead the engineering effort on the next-generation ...
... , PHILADELPHIA, Nov. 16 Shire plc ... biopharmaceutical company, announced new study results on INTUNIV ... Child and Adolescent Psychopharmacology. In this open-label safety study, ... of INTUNIV and amphetamine or methylphenidate relative to what was observed ...
Cached Medicine Technology:AMD LASERS Announces the Addition of Bart Waclawik, New Chief Operating Officer 2Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants 2Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants 3Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants 4Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants 5Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants 6Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants 7
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... widespread discrimination and health inequities. Since 2012, Massachusetts law has provided legal protections ... and business. However, the law does not protect against discrimination based on gender ...
(Date:7/29/2015)... ... ... Potomac Pilates, an elite Washington, D.C. metro area-based Pilates studio, is excited ... Potomac Pilates. On Thursday, July 30, Potomac Pilates will unveil its new name, ... will continue to offer the same classes and personal experiences their clients know and ...
(Date:7/29/2015)... Park, Pa. (PRWEB) , ... July 29, 2015 ... ... education services for autism. Parents, educators and service providers of children living with ... practices to better serve the growing demographic. , The National Autism Conference ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... Commission) CCM® credential for a five-year period, expiring November 30, 2019, during its ... credential by submitting an application demonstrating the program’s compliance with the NCCA’s Standards ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to the Miami ... or alcohol addiction and mental health disorders. Acu-detox may begin taking off in the ... from drug and alcohol addiction. Although acupuncture is not a new practice, it is ...
Breaking Medicine News(10 mins):Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 2Health News:Fenway Health Researcher: Legal Protections in Public Settings are a Critical Public Health Issue for Transgender and Gender-Nonconforming People 3Health News:Same Great Pilates Studio, New Brand - Rock the Reformer 2Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 2Health News:Miami Drug Rehab Introduces Acupuncture to Line of Holistic Healing for Addiction 3
... injection leads to dependent behavior , , THURSDAY, May 28 ... role in the disrupted functioning of the brain,s reward ... says a new study. , "If we can understand ... abuse, it could potentially suggest ways to medically counteract ...
... Digital media are changing the environment for communicating health ... New Media Landscape," University of Missouri researchers examine how ... care in the United States. Effective health communication can ... as reduce inequities in people,s access to health information ...
... Network Global Logistics (NGL), a premier provider of mission critical transportation, ... its global network of forward stocking locations (FSL,s). , ... ... a premier provider of mission critical transportation, service/spare parts logistics ...
... Jr., President & Chief Executive Officer of Concurrent Technologies Corporation ... been awarded a contract with a potential value of $90,000 ... this announcement to kick off Johnstown,s Annual Showcase for Commerce. ... Centers for Disease Control and Prevention (CDC) with Information Technology ...
... your teeth healthy. , People, who suffer from gum ... reduced their arthritic pain, number of swollen joints and the ... Researchers from the Case Western Reserve University School of ... new intervention for arthritis in the Journal of Periodontology ...
... donor factors that could affect outcomes for liver transplant ... found that donor steatosis, or fat in the liver, ... in recipients with or without HCV. However, transplants from ... affect the outcomes of HCV-positive recipients more than recipients ...
Cached Medicine News:Health News:MU researchers offer insights for advancing health communication through digital media 2Health News:NGL Expands Global Network to Service Parts Logistics Customers 2Health News:NGL Expands Global Network to Service Parts Logistics Customers 3Health News:Concurrent Technologies Corporation Awarded Contract to Support the Centers for Disease Control and Prevention with Readiness Efforts 2Health News: Treating gum disease helps rheumatoid arthritis sufferers 2Health News:Some donor factors affect outcomes for HCV-positive liver transplant recipients 2
... This combination of Penicillin, Steptomycin, and ... common forms of cell culture contamination; ... yeast, and fungi; when used at ... sterile solution is a combination of ...
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
... to buff-colored powder Activity: >=590g of gentamicin/mg (dry basis) ... Limit of Methanol: Specific Rotation (25C): +107 to ... 2 O): 3.5 to 5.5 Loss on drying: ... 25-50% C 2 + C 2a : 25-55% ...
Medicine Products: